Alpha DNA Investment Management’s AbbVie ABBV Stock Holding History

Alpha DNA Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,556	Closed	-$2.05M	–	12
2024 Q4	$2.05M	Sell	11,556 -172	-1%	-$31.6K	0.78%	23
2024 Q3	$2.32M	Sell	11,728 -5,821	-33%	-$1.09M	0.87%	13
2024 Q2	$3.01M	Buy	17,549 +5,437	+45%	+$901K	1.17%	8
2024 Q1	$2.21M	Sell	12,112 -6,210	-34%	-$1.07M	0.81%	17
2023 Q4	$2.84M	Buy	18,322 +4,806	+36%	+$701K	1.11%	12
2023 Q3	$2.01M	Buy	13,516 +158	+1%	+$23.2K	0.82%	18
2023 Q2	$1.8M	Buy	13,358 +6,539	+96%	+$959K	0.6%	32
2023 Q1	$1.09M	Sell	6,819 -3,847	-36%	-$588K	0.32%	81
2022 Q4	$1.72M	Buy	10,666 +1,458	+16%	+$224K	0.61%	23
2022 Q3	$1.24M	Buy	+9,208	New	+$1.32M	1.03%	20
2021 Q2	–	Sell	-389	Closed	-$42K	–	103
2021 Q1	$42K	Buy	389 +76	+24%	+$8.13K	0.05%	195
2020 Q4	$33K	Buy	+313	New	+$30.1K	0.04%	210

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Alpha DNA Investment Management's ABBV Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 11,556 shares — an estimated $2.05M sold.

Alpha DNA Investment Management first reported a position in ABBV in Q4 2020 and held it in 12 quarters. The position peaked at $3.01M in Q2 2024. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

Alpha DNA Investment Management reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
Alpha DNA Investment Management sold 11,556 AbbVie shares in Q1 2025, an estimated $2.05M.
Alpha DNA Investment Management first reported a position in AbbVie in Q4 2020 and held it in 12 quarters.
Alpha DNA Investment Management's AbbVie position peaked at $3.01M in Q2 2024.
3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.